{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:31:42Z","timestamp":1792200702498,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R014043\/1"],"award-info":[{"award-number":["MR\/R014043\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n To evaluate the diagnostic accuracy and imaging findings of an abbreviated biparametric MRI (bpMRI) protocol for prostate cancer (PCa) screening.<\/jats:p>\n <\/jats:sec>\n \n Materials and methods<\/jats:title>\n \n In this single-centre, prospective study, men aged 50\u201375 years were randomly selected for invitation to screening through participating general practices. Participants underwent screening with abbreviated bpMRI (axial T2-weighted and b2000 diffusion-weighted sequences) and PSA testing between October 2019 and December 2020. Screening MRIs were independently reported by two radiologists as either positive or negative by screening criteria, with a third radiologist if there was disagreement. Positive MRI or raised PSA density (PSAd) (\u2265\u20090.12\u2009ng\/mL\n 2<\/jats:sup>\n ) triggered standard-of-care NHS PCa assessment. Outcomes of the NHS assessment were collated as a composite reference standard and included multiparametric MRI\u2009\u00b1\u2009biopsy, and a 2-year healthcare record follow-up. Diagnostic accuracy was evaluated using positive predictive value (PPV).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 303 men who completed screening (median age 62 years [IQR 56, 68]), 16% (48\/303) had a positive screening MRI, and an additional 5% (16\/303) had raised PSAd alone. Of 61 men referred to secondary care, 48% (29\/61) had clinically significant PCa, with 2 (3%, 2\/61) additional diagnoses during 2-year follow-up. Of 31 men with clinically significant PCa, 87% (27\/31) had a positive screening MRI and 42% (13\/31) had raised PSAd. The PPV of the screening MRI was 59% (27\/46, 95% CI: 44, 72).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Abbreviated bpMRI may have value in PCa screening independently of PSA testing. However, prospective multicentre evaluation is needed to assess the feasibility and cost-effectiveness of MRI-based screening at a national level.<\/jats:p>\n <\/jats:sec>\n \n Key Points<\/jats:title>\n \n \n Question<\/jats:italic>\n <\/jats:bold>\n MRI may reduce over- and under-diagnosis from prostate-specific antigen (PSA) testing in PCa screening, but its use is limited by long scan times, cost, and availability<\/jats:italic>\n .\n <\/jats:p>\n \n \n Findings<\/jats:italic>\n <\/jats:bold>\n Abbreviated bpMRI identified more men with clinically significant cancer than PSAd (\u2265<\/jats:italic>\n \u2009\n 0.12<\/jats:italic>\n \u2009\n ng\/mL<\/jats:italic>\n \n 2<\/jats:italic>\n <\/jats:sup>\n ), with a PPV of 59% (95% CI: 44, 72)<\/jats:italic>\n .\n <\/jats:p>\n \n \n Clinical relevance<\/jats:italic>\n <\/jats:bold>\n Prostate MRI may improve cancer detection independently of PSA testing, with abbreviated protocols enhancing feasibility and scalability. While MRI may offer an opportunity for early diagnosis, further prospective, multicentre evaluation is needed to explore its potential role in screening settings<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Graphical Abstract<\/jats:title>\n <\/jats:sec>","DOI":"10.1007\/s00330-025-11837-1","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:38:00Z","timestamp":1754498280000},"page":"1959-1970","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE study)"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-895X","authenticated-orcid":false,"given":"Natasha","family":"Thorley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Kopcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbir S.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Brembilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Stallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonit","family":"Punwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the ReIMAGINE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"11837_CR1","unstructured":"Cancer Research UK (2025) Prostate cancer statistics. Available via https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer. Accessed 5 Jan 2025"},{"key":"11837_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M et al (2019) A 16-yr follow-up of the European Randomized study of screening for prostate cancer. Eur Urol 76:43\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009","journal-title":"Eur Urol"},{"key":"11837_CR3","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/nejmoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0 ng per millilitre. N Engl J Med 350:2239\u20132246. https:\/\/doi.org\/10.1056\/nejmoa031918","journal-title":"N Engl J Med"},{"key":"11837_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","volume":"319","author":"RM Martin","year":"2018","unstructured":"Martin RM, Donovan JL, Turner EL et al (2018) Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA 319:883. https:\/\/doi.org\/10.1001\/jama.2018.0154","journal-title":"JAMA"},{"key":"11837_CR5","doi-asserted-by":"publisher","unstructured":"Bjurlin MA, Carroll PR, Eggener S et al (2020) Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol 203(4):706\u201312. https:\/\/doi.org\/10.1097\/JU.0000000000000617","DOI":"10.1097\/JU.0000000000000617"},{"key":"11837_CR6","doi-asserted-by":"publisher","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 86:148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"11837_CR7","unstructured":"National Institute for Health and Care Excellence (NICE) (2019). Prostate cancer: diagnosis and management (NICE guideline NG131). Clinical guideline. NICE, London, UK. Updated 2021. Available from: https:\/\/www.nice.org.uk\/guidance\/ng131"},{"key":"11837_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22390","volume":"22","author":"LC Brown","year":"2018","unstructured":"Brown LC, Ahmed HU, Faria R et al (2018) Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. Health Technol Assess 22:1\u2013176. https:\/\/doi.org\/10.3310\/hta22390","journal-title":"Health Technol Assess"},{"key":"11837_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/diagnostics12020231","volume":"12","author":"G Brembilla","year":"2022","unstructured":"Brembilla G, Giganti F, Sidhu H et al (2022) Diagnostic accuracy of abbreviated bi-parametric MRI (a-bpMRI) for prostate cancer detection and screening: a multi-reader study. Diagnostics (Basel) 12:231. https:\/\/doi.org\/10.3390\/diagnostics12020231","journal-title":"Diagnostics (Basel)"},{"key":"11837_CR10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.eururo.2019.05.029","volume":"76","author":"M van der Leest","year":"2019","unstructured":"van der Leest M, Isra\u00ebl B, Cornel EB et al (2019) High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-na\u00efve men: the next step in magnetic resonance imaging accessibility. Eur Urol 76:574\u2013581. https:\/\/doi.org\/10.1016\/j.eururo.2019.05.029","journal-title":"Eur Urol"},{"key":"11837_CR11","doi-asserted-by":"publisher","unstructured":"Twilt JJ, Saha A, Bosma JS et al (2025) Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study. Eur Urol 87:240\u2013250. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.035","DOI":"10.1016\/j.eururo.2024.09.035"},{"key":"11837_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bju.14759","volume":"124","author":"M Alabousi","year":"2019","unstructured":"Alabousi M, Salameh JP, Gusenbauer K et al (2019) Biparametric vs multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatment-na\u00efve patients: a diagnostic test accuracy systematic review and meta-analysis. BJU Int 124:209\u2013220","journal-title":"BJU Int"},{"key":"11837_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.euo.2023.03.009","volume":"6","author":"D Eldred-Evans","year":"2023","unstructured":"Eldred-Evans D, Tam H, Sokhi H et al (2023) An evaluation of screening pathways using a combination of magnetic resonance imaging and prostate-specific antigen: results from the IP1-PROSTAGRAM study. Eur Urol Oncol 6:295\u2013302. https:\/\/doi.org\/10.1016\/j.euo.2023.03.009","journal-title":"Eur Urol Oncol"},{"key":"11837_CR14","doi-asserted-by":"publisher","first-page":"e059482","DOI":"10.1136\/bmjopen-2021-059482","volume":"12","author":"R Nam","year":"2022","unstructured":"Nam R, Patel C, Milot L et al (2022) Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial. BMJ Open 12:e059482. https:\/\/doi.org\/10.1136\/bmjopen-2021-059482","journal-title":"BMJ Open"},{"key":"11837_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00330-023-10019-1","volume":"34","author":"E Messina","year":"2024","unstructured":"Messina E, La Torre G, Pecoraro M et al (2024) Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial\u2014prostate cancer secondary screening in Sapienza (PROSA). Eur Radiol 34:204\u2013213. https:\/\/doi.org\/10.1007\/s00330-023-10019-1","journal-title":"Eur Radiol"},{"key":"11837_CR16","doi-asserted-by":"publisher","first-page":"e048144","DOI":"10.1136\/bmjopen-2020-048144","volume":"11","author":"T Marsden","year":"2021","unstructured":"Marsden T, Lomas DJ, McCartan N et al (2021) ReIMAGINE prostate cancer screening study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI. BMJ Open 11:e048144. https:\/\/doi.org\/10.1136\/bmjopen-2020-048144","journal-title":"BMJ Open"},{"key":"11837_CR17","doi-asserted-by":"publisher","first-page":"e000057","DOI":"10.1136\/bmjonc-2023-000057","volume":"2","author":"CM Moore","year":"2023","unstructured":"Moore CM, Frangou E, McCartan N et al (2023) Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study. BMJ Oncol 2:e000057. https:\/\/doi.org\/10.1136\/bmjonc-2023-000057","journal-title":"BMJ Oncol"},{"key":"11837_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340\u2013351","journal-title":"Eur Urol"},{"key":"11837_CR19","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJLH Van Leenders","year":"2020","unstructured":"Van Leenders GJLH, Van Der Kwast TH, Grignon DJ et al (2020) The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 44:e87\u2013e99. https:\/\/doi.org\/10.1097\/PAS.0000000000001497","journal-title":"Am J Surg Pathol"},{"key":"11837_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","volume":"22","author":"EB Wilson","year":"1927","unstructured":"Wilson EB (1927) Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 22:209\u2013212. https:\/\/doi.org\/10.1080\/01621459.1927.10502953","journal-title":"J Am Stat Assoc"},{"key":"11837_CR21","doi-asserted-by":"publisher","unstructured":"Schoots IG, Haider MA, Punwani S, Padhani AR (2025) MRI in prostate cancer screening: a review and recommendations, from the AJR special series on screening. AJR Am J Roentgenol. https:\/\/doi.org\/10.2214\/AJR.24.32588","DOI":"10.2214\/AJR.24.32588"},{"key":"11837_CR22","doi-asserted-by":"publisher","first-page":"6909","DOI":"10.1007\/s00330-021-07754-8","volume":"31","author":"E Cornford","year":"2021","unstructured":"Cornford E, Cheung S, Press M et al (2021) Optimum screening mammography reading volumes: evidence from the NHS breast screening programme. Eur Radiol 31:6909\u20136915. https:\/\/doi.org\/10.1007\/s00330-021-07754-8","journal-title":"Eur Radiol"},{"key":"11837_CR23","doi-asserted-by":"publisher","unstructured":"van Lohuizen Q, Roest C, Simonis FFJ et al (2024) Assessing deep learning reconstruction for faster prostate MRI: visual vs. diagnostic performance metrics. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-024-10771-y","DOI":"10.1007\/s00330-024-10771-y"},{"key":"11837_CR24","doi-asserted-by":"publisher","unstructured":"de Rooij M, Allen C, Twilt JJ et al (2024) PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-024-10795-4","DOI":"10.1007\/s00330-024-10795-4"},{"key":"11837_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/jmri.25372","volume":"45","author":"MD Greer","year":"2017","unstructured":"Greer MD, Brown AM, Shih JH et al (2017) Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: a multireader study. J Magn Reson Imaging 45:579\u2013585. https:\/\/doi.org\/10.1002\/jmri.25372","journal-title":"J Magn Reson Imaging"},{"key":"11837_CR26","doi-asserted-by":"crossref","unstructured":"Lee CH, Vellayappan B, Tan CH (2022) Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis. Br J Radiol 95:20210509","DOI":"10.1259\/bjr.20210509"},{"key":"11837_CR27","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1148\/radiol.13122233","volume":"269","author":"AB Rosenkrantz","year":"2013","unstructured":"Rosenkrantz AB, Kim S, Lim RP et al (2013) Prostate cancer localization using multiparametric MR imaging: Comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology 269:482\u2013492. https:\/\/doi.org\/10.1148\/radiol.13122233","journal-title":"Radiology"},{"key":"11837_CR28","unstructured":"Prostate Cancer UK (2024) TRANSFORM trial. Available via https:\/\/prostatecanceruk.org\/research\/transform-trial. Accessed 14 Mar 2024"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11837-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:19:55Z","timestamp":1772716795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11837-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["11837"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11837-1","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Professor Shonit Punwani.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: F.G. reports consulting fees from SpectraCure and Procept outside of the submitted work. He has received speaker fees from Bayer and Siemens. He is a member of the Scientific Editorial Board of\n European Radiology\n (section: urogenital). As such, they have not participated in the selection or review processes for this article. S.P. reports consulting fees from NVISION IMAGING, Gold Standard Phantoms and Quibim outside of the submitted work. The remaining authors declare no conflicts of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors (T.P.) has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained. Ethical approval was granted by the London\u2014Stanmore Research Ethics Committee, Health Research Authority (ref: 19\/LO\/1129).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participants from the ReIMAGINE Screening Study have been included in a previous publication. Primary outcomes were reported in Moore et al [\n \n ]\n \n . In addition, the study protocol has been previously published in Marsden et al [\n \n ]\n \n .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}